May 17, 2021 01:16 PM EDT

SCOTUS declines to review Enbrel biosimilar case, teeing up 30+ years of exclusivity and $20B more for Amgen’s blockbuster

Zachary Brennan

Senior Editor

As the House Oversight Committee is set to grill AbbVie CEO Richard Gonzalez on Tuesday over tactics to block competition for its best-selling drug of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

SCOTUS declines to review Enbrel biosimilar case, teeing up 30+ years of exclusivity and $20B more for Amgen’s blockbuster

Zachary Brennan

Senior Editor

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Roivant brings rare disease program closer as Immunovant CEO retires

China startup injects CRISPR therapy into the brain for the first time

FDA approves Dupixent for hives, rejects new Eylea dosing schedule

Trodelvy and Keytruda combo succeeds in Phase 3 breast cancer study

Exclusive: VelaVigo inks another US biotech deal as China drug development scene booms

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

SCO­TUS de­clines to re­view En­brel biosim­i­lar case, tee­ing up 30+ years of ex­clu­siv­i­ty and $20B more for Am­gen’s block­buster

Senior Editor

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

SCOTUS declines to review Enbrel biosimilar case, teeing up 30+ years of exclusivity and $20B more for Amgen’s blockbuster